Hengrui's Strong Show at ASCO 2026
Let's dive straight into the buzz from the 2026 ASCO Annual Meeting, where Hengrui Pharma made waves, showcasing more than 90 studies. Now, when a company rolls out that many studies in one go, they're not just trying to grab headlines—they're signaling some serious commitment to cancer research. From breast to colorectal and even liver cancers, Hengrui's trying to make their mark across the board and not too quietly either.
Breast Cancer: New Paths, Old Challenges
Breast cancer research took center stage with two standouts. The HELEN-Trio 011 study was a talker, pushing the boundary with camrelizumab and chemotherapy, hitting a 57.5% pathological complete response (pCR) compared to a lesser 45.4% with just chemo. It's all about that incremental edge, folks.
Meanwhile, a new regimen mixing paclitaxel, trastuzumab, and pyrotinib, dubbed nab-PHPy, showed it could hold its ground against the standard TCHP for HER2-positive breast cancer. You know, options are the name of the game in medicine. When standard regimens get too rough on patients, alternatives like this are gold dust.
Gastrointestinal: Colorectal and Liver Insights
In the gastrointestinal realm, that HORIZON-CRC01 study caught my eye. New anti-HER2 ADCs are stepping into the spotlight with a median progression-free survival of 5.5 months, a step up from the old conventional chemotherapy footing. Then there's the liver cancer frontier with the promising duo of camrelizumab plus apatinib and TACE, pushing PFS further than just TACE alone. It's these combos that could shift treatment paradigms.
"In the trenches of oncology, it's all about squeezing out those extra months of survival—every little bit counts," a sentiment that holds water more than ever.
Urological and Supportive Cancer Treatments: Pushing Boundaries
Come to urological cancers and the word is breakthroughs. Fluzoparib and the usual suspects of abiraterone acetate and prednisone made headlines, particularly fluzoparib nudging the median radiographic PFS up for metastatic castration-resistant prostate cancer (mCRPC). For me, seeing treatments extend time without progression is akin to finding a diamond in the rough.
Over in the bladder cancer arena, the anti-Nectin-4 ADC combined with adebrelimab demonstrated impressive results: pCR rates hitting 48.1%. These are the kinds of figures that could change how patients face pre-surgery protocols.
On the supportive care side, antiemetics like Fosrolapitant are proving their mettle. It's not just about killing the cancer, but making the journey less of a nightmare. The Phase III PROTECT study gives a nod to that with its solid performance in reducing chemo-induced nausea.
Looking Ahead: Hengrui's Continued Push
With 16 approved oncology medicines and another 60 in the cooker, Hengrui seems far from slowing down. They've got over 150 clinical trials active worldwide; it shows how they're not just dabbling but playing for keeps. The ASCO conference this year is but a snapshot of their expanding play on the oncology stage, challenging the norms and steadily advancing their pipeline.
As other pharmas might take things a tad more cautiously, Hengrui is putting the pedal to the metal on their R&D investment. With a solid showing at ASCO 2026, they're lining up on deck with potential game-changers. Not every bet in this high-stakes area pays off, but Hengrui is making sure they've got a seat at the table with each showing.
